한국어
English
日本語
中文(简体)
Lecraza Tablet 80 mg (Lazertinib Mesylate Dihydrate)
96.48mg
Tablet · Prescription medication
Yuhan Corporation
Lazertinib mesylate hydrate is an anti-cancer ingredient that inhibits the growth of specific cancer cells.
MFDS ingredient code M280186
Lazertinib mesylate hydrate is a targeted anti-cancer drug used for the treatment of non-small cell lung cancer. This ingredient blocks the activity of specific proteins within cancer cells to suppress their proliferation. It is primarily included in medications for the purpose of disrupting cancer cell growth signaling pathways.
This ingredient inhibits the activity of specific receptors on the surface of cancer cells, blocking signals that allow the cancer cells to grow or divide. As a result, the proliferation of cancer cells is suppressed, and the progression of cancer can be slowed. It has relatively less impact on normal cells, acting selectively.
Approved uses differ by product. Check each product's information for its actual use.
Lazertinib mesylate hydrate exhibits high selectivity for specific mutated receptors compared to other targeted anti-cancer drugs. This characteristic reduces side effects while enhancing therapeutic efficacy. It is also effective against brain metastatic cancer cells, broadening the treatment scope.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.